A new University of Gothenburg study has paved the way for the first drug treatment for sleep apnea. Compared to before receiving the treatment, breathing pauses decreased with on average more than 20 per hour for patients given the drug.
The treatment that has been tested is carbonic anhydrase (CA) inhibition, CA being an enzyme that serves to maintain a balance between carbonic acid and carbon dioxide in the body. Several drugs with CA inhibitory properties are already available on the market, and used for treatment of glaucoma, epilepsy and other disorders.
Previous research has not systematically tested whether CA inhibitors also might be used to treat obstructive sleep apnea. The current study was a randomized double-blind clinical trial, and 59 patients with moderate or severe sleep apnea completed it. Patients were randomly assigned to two groups receiving either 400 or 200 mg of the CA inhibitor, and a third group (the control group) that received placebo. The study lasted for four weeks.
Fewer breathing pauses
The results show that, overall, the treatment reduced the number of breathing pauses and promoted oxygenation during the night. A few patients experienced side effects, such as headache and breathlessness, which were more common in those receiving the highest dose.
The study results together with established safety data of the drug sulthiame provide support for continued research on CA inhibition as a new potential treatment for obstructive sleep apnea.
“Among the patients who received the higher dosage of the drug, the number of breathing pauses decreased by approximately 20 per hour. For just over a third of patients in the study, only half of their breathing pauses were left, and in one in five the number fell by at least 60 percent,” says Jan Hedner, Professor of Pulmonary Medicine.
The fact that several approved drugs in the CA inhibitor category are available on the market makes fast-tracking development of an approved drug for sleep apnea practicable. The drug used in this clinical trial was sulthiame, which is sometimes used to treat epilepsy in children.
Treatment options needed
Today, treatment for a patient with sleep apnea is either an oral appliance therapy or a CPAP (Continuous Positive Airway Pressure) mask. Both help to maintain airway patency during sleep.
“These therapy options take time to get used to and, since they frequently are perceived as intrusive or bulky. Insufficient user time is therefore common. If we develop an effective drug, it will therefore make life easier for many patients and, in the long run, potentially also save more lives,” says Ludger Grote, Senior Lecturer at Sahlgrenska Academy, University of Gothenburg.
The German pharmaceutical company Desitin Arzneimittel GmbH funded the trial, and the results are published in the American Journal of Respiratory and Critical Care Medicine.
- A Healthy Lifestyle Can Offset a High Genetic Risk for Stroke, According to New Research by UTHealth Houston
Newswise — People who are genetically at higher risk for stroke can lower that risk by as much as 43% by adopting a healthy cardiovascular lifestyle, according to new research led by UTHealth Houston, which was published today in the Journal of the American Heart Association. The study included 11,568 adults from ages 45 to 64 who… Read more: A Healthy Lifestyle Can Offset a High Genetic Risk for Stroke, According to New Research by UTHealth Houston - Life Time Reaches 30 Years of Inspiring Health and HappinessFrom first opening in 1992 to nearly 160 athletic country clubs and more than one billion visits, countless stories of extraordinary transformation, life-altering events and strong community serve to warm the heart CHANHASSEN, Minn., July 15, 2022 /PRNewswire/ — Life Time (NYSE: LTH), the nation’s premier healthy lifestyle brand, opened its first club in a Brooklyn Park, Minn. strip mall 30… Read more: Life Time Reaches 30 Years of Inspiring Health and Happiness
- Spectruth’s New Metaverse for Therapy Treatment Coming Soon.
Ukrainian “SAFE” not-for-profit Foundation commissioned Spectruth’s development of a 3D virtual therapy metaverse.KYIV, KYIV OBLAST, UKRAINE, July 10, 2022 /EINPresswire.com/ — The future is bright for anyone seeking therapy despite lock-downs, lack of local therapists or high costs. “SAFE” Premier Therapy Clinic of Ukraine, a charitable foundation has commissioned a new 3D virtual therapy clinic… Read more: Spectruth’s New Metaverse for Therapy Treatment Coming Soon. - Aussie Company Care A2+ Gains FDA Approval to Address US Infant Formula Shortages
Up to 4.8 million tins of premium baby formula to help address U.S. supply chain crisis SYDNEY (Newswire.com) – Care A2+, an Australian health and wellness company, today announced it has been approved by the United States Food & Drug Administration (FDA) to deliver up to 4.8 million tins of Australian-made Care A2+ Premium Infant Formula with… Read more: Aussie Company Care A2+ Gains FDA Approval to Address US Infant Formula Shortages - FDA Infant Formula Update: July 8, 2022
Today, the U.S. Food and Drug Administration is providing an update on additional steps it has taken that will lead to more infant formula available in the U.S. under the agency’s recent increased flexibilities. Company (Product Origin): Care A2+ (Australia) Product(s): Care A2+ 0-12 Months Infant Formula Type of Formula: General Estimated Quantity: 4.875 million cans (about 8.6 million pounds… Read more: FDA Infant Formula Update: July 8, 2022
